Fairvalue-Calculator Fairvalue-Calculator
EN DE

McKesson Corporation (M1CK34) Fair Value & Analysis

Healthcare · BR · Market cap R$481B

PriceR$990.72
Fair ValueR$188.90
Upside-80.9%
Quality94/100
Evidence: High Range R$140.35 – R$237.46

Analysis

McKesson Corporation (M1CK34) currently trades at R$990.72, while our model-based Fair Value estimate is R$188.90 — implying the stock looks roughly 80.9% overvalued today. We read business quality at 94/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).

About the company

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: North American Pharmaceutical, Oncology & Multispecialty, Prescription Technology Solutions, and Medical-Surgical Solutions. The company distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products; delivers products to retail pharmacies, hospitals, long-term care centers, clinics, and institutions; and provides logistics and distribution services for manufacturers. It also provides consulting, outsourcing, technological, and other services, as well as sells financial, operational, and clinical solutions to pharmacies; gene therapy with InspiroGene, practice consulting, and vaccine distribution services; and technology solutions, as well as research, insights, technologies, and services to improve cancer and specialty care. In addition, the company helps in solving medication access, aff…

Open the full interactive analysis →

Similar stocks

Cencora, Inc (C1CO34) -89% Cardinal Health, Inc (CAH) -38% Sigma Healthcare Limited (SIGGF) -73% Sitka Gold Corp (SIG) -88% Shanghai Pharmaceuticals Holding (601607) +183% Henry Schein, Inc (HSIC) -15%

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.